现代医药卫生2024,Vol.40Issue(20) :3568-3572.DOI:10.3969/j.issn.1009-5519.2024.20.029

代谢相关脂肪性肝病的诊治进展

Progress in diagnosis and treatment of metabolic associated fatty liver disease

刘钰 骆骁骐 谭晓燕
现代医药卫生2024,Vol.40Issue(20) :3568-3572.DOI:10.3969/j.issn.1009-5519.2024.20.029

代谢相关脂肪性肝病的诊治进展

Progress in diagnosis and treatment of metabolic associated fatty liver disease

刘钰 1骆骁骐 2谭晓燕1
扫码查看

作者信息

  • 1. 大连医科大学附属第一医院,辽宁大连 116011
  • 2. 南方医科大学,广东 广州 510515
  • 折叠

摘要

代谢相关脂肪性肝病是一种与肥胖、2型糖尿病和高脂血症相关的慢性肝病,其发病率呈逐年上升趋势,严重影响患者的生活质量,给患者及社会带来沉重的医疗负担.其发病机制涉及多种因素,如二次打击与多重打击、幽门螺杆菌感染及交感神经的过度激活等,治疗方式有改变生活方式、改善胰岛素抵抗、调节肠道菌群、巨噬细胞靶向治疗等方面.该文就代谢相关脂肪性肝病的诊治进展作一综述.

Abstract

Metabolic associated fatty liver disease is a chronic liver disease associated with obesity,type 2 diabetes and hyperlipidemia.The incidence of metabolic associated fatty liver disease is increasing year by year,which seriously affects the quality of life of patients and brings heavy medical burden to patients and so-ciety.Its pathogenesis involves a variety of factors,such as two-hit and multiple-hit,Helicobacter pylori infec-tion and excessive activation of sympathetic nerves.The treatment methods include changing lifestyle,impro-ving insulin resistance,regulating intestinal flora,and macrophage targeted therapy.This article reviews the progress in the diagnosis and treatment of metabolic associated fatty liver disease.

关键词

代谢相关脂肪性肝病/非酒精性脂肪性肝病/代谢综合征/胰岛素抵抗/幽门螺杆菌感染/综述

Key words

Metabolic associated fatty liver disease/Nonalcoholic fatty liver disease/metabolic syn-drome/Insulin resistance/Helicobacter pylori infection/Review

引用本文复制引用

出版年

2024
现代医药卫生
重庆市卫生信息中心

现代医药卫生

影响因子:0.758
ISSN:1009-5519
段落导航相关论文